Jump to content

Grand River Aseptic Manufacturing

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Akrasia25 (talk | contribs) at 01:51, 5 February 2021 (Some CE). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Grand River Aseptic Manufacturing (GRAM)
Company typePrivate company
IndustryPharmaceuticals
Founded2010
HeadquartersGrand Rapids, MI, U.S.
Key people
Tom Ross, CEO[1] Nick Bykerk vice president of finance[2]
ServicesClinical and commercial sterile manufacturing
Number of employees
200(2020)[3]
Websitegrandriverasepticmfg.com

Grand River Aseptic Manufacturing (GRAM) is a clinical and commercial sterile manufacturing contractor to the pharmaceutical industry. It has lyophilization, terminal sterilization, analytical, microbiological testing services.[1]

GRAM was founded in 2010 by the Van Andel Institute and Grand Valley State University.

Arlington Capital Partners, a private equity firm in Washington, D.C. made a majority investment in GRAM in 2017.

In June 2020, GRAM finished a $60 million expansion to install a 61,500-square-foot fill-finish injectable facility on the same site to triple GRAM's manufacturing footprint to more than 100,000 square feet of production space.[4]

In 2020, BARDA and Johnson & Johnson contracted with GRAM to do fill and finish services for vaccines in response to the coronavirus pandemic.

History

GRAM was founded in 2010 by Van Andel Institute and Grand Valley State University.[1]

Arlington Capital Partners, a private equity firm in the Washington, D.C. made a majority investment in GRAM in 2017.[2]

Covid vaccine facility

In June 2020, GRAM finished a $60 million expansion to install another fill-finish injectables facility with the plan to market it to U.S. drugmakers.[4] The 61,500-square-foot facility included in that expansion tripled GRAM's manufacturing footprint to more than 100,000 square feet of production space.[4]

GRAM chose SKAN isolators, a Bausch+Ströbel filler and an IMA lyophilizer.[2][4] The facility was qualified in July 2020.[5]

In August 2020, BARDA awarded GRAM a one-year, $160M contract to provide fill and finish services for vaccines in response to the coronavirus pandemic.[6]

In September, GRAM agreed with Janssen Pharmaceuticals, one of the companies of Johnson & Johnson, to support the manufacture of its SARS-CoV-2 vaccine candidate, including technology transfer and fill and finish manufacture.[7]

Awards

In 2017, 2018, 2019, and 2020 Inc. Magazine ranked GRAM as one of the Inc. 5000 fastest-growing private companies in America.[3] The company won West Michigan's Best and Brightest Companies to Work For in 2017 and 2020.[3]

References

  1. ^ a b c Martinez, Shandra. "Ex-Perrigo VP promoted to CEO of Grand Rapids medical supplier".
  2. ^ a b c "GRAM Continues Aggressive Expansion in Parenterals".
  3. ^ a b c "GRAM website". GRAM.
  4. ^ a b c d Blankenship, Kyle. "Johnson & Johnson signs on Michigan's Grand River to help with COVID-19 vaccine finishing work".
  5. ^ "AEC Firms Aid Virus Vaccine 'Warp Speed' Market Push".
  6. ^ "Army Taps Grand River Aseptic Manufacturing for $160M COVID-19 Vaccine Production Support Contract".
  7. ^ "Ramping Up COVID-19 Vaccine Fill and Finish Capacity".